Loading stock data…
Ardelyx, Inc. (ARDX)
$5.25-0.30 (-5.32%)
Market OpenUpdated 3:09 PM EDT
Ardelyx, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ardelyx, Inc. in the Healthcare sector is trading at $5.36 with a market capitalization of $1.3B. Wall Street consensus targets $16.30 (10 analysts), implying a +204.4% move over the next 12 months. The stock is currently 36% below its 52-week high of $8.40, remaining 12.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +204.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $94.47M↓ | $125.22M↑ | $110.33M↑ | $97.66M↑ | $74.11M |
| Gross Profit | $89.66M↓ | $114.37M↑ | $106.35M↑ | $85.26M↑ | $61.81M |
| Operating Income | -$32.79M↓ | $5.10M↑ | $4.67M↑ | -$14.39M↑ | -$36.35M |
| Net Income | -$37.60M↓ | -$407,000↑ | -$969,000↑ | -$19.08M↑ | -$41.14M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritabl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.07%
Volume
Today's trading volume
6.70M
Recent News
ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle
The U.S. Court of Appeals for the D.C. Circuit said federal law prevents judges from reviewing Medicare’s decision to include certain kidney drugs in the dialysis payment bundle.
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction
This biotech specializing in gastrointestinal and cardiorenal therapies reported a notable insider sale following strong 1-year returns.
What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?
Ardelyx, Inc. (NASDAQ:ARDX) is among the best low priced stocks to get rich in 2026. On June 16, Ladenburg started coverage on Ardelyx, Inc. (NASDAQ:ARDX) with a Buy rating and a price target of $16. According to TheFly, the company is currently focused on expanding demand for Ibsrela, sustaining sales momentum for Xphozah, growing its […]
Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility
Ardelyx stock snapshot and recent performance Ardelyx (ARDX) has been drawing more attention after recent share price moves, with the stock up 3.2% over the past day and 7.2% over the past week, despite being down 12.4% over the past month. See our latest analysis for Ardelyx. Recent trading has been choppy, with the share price sliding over the past month but roughly flat over the past quarter, while the 1 year total shareholder return of 55.7% reflects a much stronger longer term...